Choroideremia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Choroideremia – Drugs In Development, 2024 report and make more profitable business decisions.
Choroideremia is an X-linked chorioretinal dystrophy characterized by the diffuse, progressive degeneration of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris. It is caused by a mutation in the CHM gene. Symptoms include night blindness, difficulty in peripheral vision, lack of visual acuity, and loss of ability to see colors. The diagnosis of choroideremia can be done by characteristic fundus findings and family history. It can be confirmed through direct genetic testing or by immunoblot analysis with anti-REP-1 antibody.
The Choroideremia drugs in development market research report provide comprehensive information on the therapeutics under development for Choroideremia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroideremia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Choroideremia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Choroideremia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Choroideremia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Choroideremia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4D Molecular Therapeutics IncCopernicus Therapeutics Inc
Curative Biotechnology Inc
F. Hoffmann-La Roche Ltd
Kiora Pharmaceuticals Inc
University Hospital Tubingen
University of Pennsylvania
Zhongmou Therapeutics
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Choroideremia reports